23:03 , Jul 18, 2019 |  BC Extra  |  Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi's newly closed third fund, its largest ever, will depart from the VC's prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
23:31 , Jul 16, 2019 |  BC Extra  |  Company News

Genentech adds three discovery partnerships to build out pipeline

Through a trio of deals with Convelo, Skyhawk and Sosei Heptares announced Tuesday, Genentech is adding programs that could refresh its early stage neurology pipeline, as well as its oncology and other early R&D. Global...
00:35 , Feb 9, 2019 |  BC Extra  |  Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...
23:37 , Feb 8, 2019 |  BioCentury  |  Finance

Medicxi’s orexin dream deal

Sleep disorder spinouts Orexia Ltd. and Inexia Ltd. were created to marry Medicxi’s keen interest in agonizing orexin and Heptares Therapeutics Ltd.’s desire to find creative ways to fund its pipeline. Medicxi will invest up...
18:57 , Feb 7, 2019 |  BC Week In Review  |  Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
21:47 , Feb 4, 2019 |  BC Extra  |  Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
23:44 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:PTE) hired Matt Kemp as chief commercial officer, a newly created position. He was CCO at Dendreon Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China)....
22:41 , Nov 8, 2018 |  BC Innovations  |  Product R&D

JLABS seeks lung cancer solutions in Shanghai

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...